AFP and neoplasm: However, patients in the lenvatinib group with macrovascular invasion (HR, 1.8; 95% CI, 1.0–3.0; p = 0.032), maximal intrahepatic tumor size > 5 cm (HR, 2.0; 95% CI, 1.2–3.2; p = 0.008), or AFP level > 1000 ng/mL (HR, 1.8; 95% CI, 1.0–3.1; p = 0.034) showed inferior OS outcomes compared to the HAIC group.